Parvus Central

The Gateway To Our Technology & Company

Parvus Therapeutics’ Navacim platform has the potential to generate multiple unique “First in Class” breakthrough therapeutics for the treatment of autoimmune diseases. Autoimmune diseases result from a failure of the body’s immune system to differentiate between “self” and an invading pathogen. In these diseases, once the original pathogen is eliminated, the immune system continues to attack, destroying normal tissues and organs, resulting in diseases such as type 1 diabetes (T1D), multiple sclerosis (MS), and at least eighty other autoimmune diseases. These diseases are not only devastating to an individual’s quality of life and shorten their expected life span, but the costs in health care and lost productivity are astronomical. We believe that Parvus has a powerful and completely novel solution. The Parvus proprietary drug candidates, called NavacimsTM, are designed to restore immune tolerance, i.e. the immune system’s ability to differentiate a pathogen from “self”.

This is the hub of our website and the gateway to our company. We invite you to discover more about our technology and follow along as we take our first therapeutic candidate, NavacimTD, from the laboratory to the clinic as an entirely new treatment for diabetes.

Investors

Multi-pronged Commercialization Strategy

The Parvus value creation and commercialization strategy is to negotiate partnerships with major pharmaceutical companies to undertake the clinical and commercial development of most of our product candidates. We will, however, reserve at least one in-house candidate to be developed by Parvus to clinical Proof of Concept (PoC). This strategy offers us the potential for optimizing the route to PoC as well as multiple “shots on goal” for successful clinical and commercial development of Navacims.

We currently are in advanced discussions with several pharmaceutical companies and look forward to expanding our portfolio of potential partners interested in advancing the breadth of the Navacim therapeutic platform.

Parvus is a privately held corporation based in Calgary, Alberta, Canada and has been financed to date by approximately $4 million from private investors and over $16 million from granting agencies and research charities in Canada and the United States. Notable amongst our supporters are the Juvenile Diabetes Research Foundation International (JDRF), The Government of Canada (NRC/IRAP, NSERC, CIHR), The Government of Alberta (AHFMR), and University Technologies International LP.

Development Partners

Disease-Specific, Compositionally Alike

Each Navacim shares a core structure: a pegylated iron oxide nanoparticle coated with a human immune system protein possessing a disease-specific peptide sequence. This peptide causes the expansion in the numbers of normally rare, naturally occurring immune cells called regulatory T-cells (T-Regs). The normal role of T-regs is to dampen down the immune response once the particular pathogen has been removed, targeting and eliminating the specific disease-producing cells. T-regs rebalance the immune system and restore immune tolerance.

Parvus’ Navacims are extremely disease-specific. We have been able to show in multiple animal models of disease that Navacims will halt, even cure the disease. Furthermore, we have shown no “off target” affects in extensive animal studies of toxicity. Navacims are designed to halt or cure the disease without negatively affecting the body’s normal immune functions. We know of no other therapies, currently on the market or in development, that cause disease-specific expansion of T-regs in vivo (in the body). In short, Navacims have the potential to be “game changers” in the treatment of these devastating and costly diseases.